Disseminated Chickenpox Following Live Varicella Vaccination in a Crohn's Disease Patient on Combination Immunosuppression.

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY
Case Reports in Gastrointestinal Medicine Pub Date : 2025-01-20 eCollection Date: 2025-01-01 DOI:10.1155/crgm/6088333
Quintin Solano, Sarah Uttal, Peter D R Higgins, Jeffrey A Berinstein
{"title":"Disseminated Chickenpox Following Live Varicella Vaccination in a Crohn's Disease Patient on Combination Immunosuppression.","authors":"Quintin Solano, Sarah Uttal, Peter D R Higgins, Jeffrey A Berinstein","doi":"10.1155/crgm/6088333","DOIUrl":null,"url":null,"abstract":"<p><p>Novel therapeutics used in the treatment of inflammatory bowel disease pose an increased risk of viral reactivation in patients. We present a case of a patient with refractory Crohn's disease (CD) who developed primary varicella (chickenpox) of a vaccine-viral strain after receiving combination immunosuppression with high-dose corticosteroids, tumor necrosis factor inhibitor (TNFi), and a Janus kinase inhibitor (JAKi) in the hospital. While this patient recovered and did not experience long term adverse effects, her case provides an opportunity for improvement. To improve safety, healthcare facilities should develop protocols that use electronic medical records enhanced with clinical decision support systems to identify and protect immunocompromised patients from inappropriate live vaccinations.</p>","PeriodicalId":45645,"journal":{"name":"Case Reports in Gastrointestinal Medicine","volume":"2025 ","pages":"6088333"},"PeriodicalIF":0.6000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772060/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Gastrointestinal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crgm/6088333","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Novel therapeutics used in the treatment of inflammatory bowel disease pose an increased risk of viral reactivation in patients. We present a case of a patient with refractory Crohn's disease (CD) who developed primary varicella (chickenpox) of a vaccine-viral strain after receiving combination immunosuppression with high-dose corticosteroids, tumor necrosis factor inhibitor (TNFi), and a Janus kinase inhibitor (JAKi) in the hospital. While this patient recovered and did not experience long term adverse effects, her case provides an opportunity for improvement. To improve safety, healthcare facilities should develop protocols that use electronic medical records enhanced with clinical decision support systems to identify and protect immunocompromised patients from inappropriate live vaccinations.

克罗恩病患者联合免疫抑制接种活水痘后播散性水痘。
用于治疗炎症性肠病的新疗法增加了患者病毒再激活的风险。我们报告了一例难治性克罗恩病(CD)患者,在医院接受高剂量皮质类固醇、肿瘤坏死因子抑制剂(TNFi)和Janus激酶抑制剂(JAKi)联合免疫抑制后,发生了疫苗病毒株的原发性水痘(水痘)。虽然这名患者康复了,没有经历长期的不良反应,但她的病例提供了一个改善的机会。为了提高安全性,医疗机构应制定方案,使用经临床决策支持系统增强的电子病历,以识别和保护免疫功能低下的患者免受不适当的活疫苗接种。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Case Reports in Gastrointestinal Medicine
Case Reports in Gastrointestinal Medicine GASTROENTEROLOGY & HEPATOLOGY-
自引率
0.00%
发文量
33
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信